Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Total Liabilities: 2018-2025

  • Dr Reddys Laboratories' Total Liabilities rose 42.13% to $1.8 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $1.8 billion, marking a year-over-year increase of 42.13%. This contributed to the annual value of $1.8 billion for FY2025, which is 42.13% up from last year.
  • Latest data reveals that Dr Reddys Laboratories reported Total Liabilities of $1.8 billion as of Q1 2025, which was up 42.13% from $1.3 billion recorded in Q1 2024.
  • Dr Reddys Laboratories' Total Liabilities' 5-year high stood at $1.8 billion during Q1 2025, with a 5-year trough of $1.1 billion in Q1 2023.
  • Moreover, its 3-year median value for Total Liabilities was $1.3 billion (2024), whereas its average is $1.4 billion.
  • In the last 5 years, Dr Reddys Laboratories' Total Liabilities dropped by 17.95% in 2023 and then surged by 42.13% in 2025.
  • Over the past 5 years, Dr Reddys Laboratories' Total Liabilities (Quarterly) stood at $1.3 billion in 2021, then increased by 6.65% to $1.3 billion in 2022, then declined by 17.95% to $1.1 billion in 2023, then grew by 16.09% to $1.3 billion in 2024, then spiked by 42.13% to $1.8 billion in 2025.
  • Its Total Liabilities stands at $1.8 billion for Q1 2025, versus $1.3 billion for Q1 2024 and $1.1 billion for Q1 2023.